COPD is a disease with an indeterminate course and variable prognosis. Its prognosis depends on several factors including genetic predisposition, environmental exposures, comorbidities, and, to a lesser degree, acute exacerbations.
Although short-term survival for patients with COPD and respiratory failure depends on the overall severity of acute illness, long-term survival is primarily influenced by the severity of COPD and the presence of comorbid conditions. Traditionally, prognosis has been reported based on the FEV₁, which is a part of pulmonary function testing. A meta-regression analysis showed a significant correlation between increased FEV₁ and lower risk of COPD exacerbation.[253]Zider AD, Wang X, Buhr RG, et al. Reduced COPD exacerbation risk correlates with improved FEV1: a meta-regression analysis. Chest. 2017 Sep;152(3):494-501.
http://www.ncbi.nlm.nih.gov/pubmed/28483609?tool=bestpractice.com
In addition to the FEV₁, other factors that predict prognosis are weight (very low weight is a negative prognostic factor, with one meta-analysis identifying a significant association between low body mass index and accelerated FEV₁ decline), distance walked in 6 minutes, and degree of shortness of breath with activities.[254]Guo Y, Zhang T, Wang Z, et al. Body mass index and mortality in chronic obstructive pulmonary disease: a dose-response meta-analysis. Medicine (Baltimore). 2016 Jul;95(28):e4225.
https://journals.lww.com/md-journal/fulltext/2016/07120/Body_mass_index_and_mortality_in_chronic.50.aspx
http://www.ncbi.nlm.nih.gov/pubmed/27428228?tool=bestpractice.com
[255]Sun Y, Milne S, Jaw JE, et al. BMI is associated with FEV1 decline in chronic obstructive pulmonary disease: a meta-analysis of clinical trials. Respir Res. 2019 Oct 29;20(1):236.
https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-019-1209-5
http://www.ncbi.nlm.nih.gov/pubmed/31665000?tool=bestpractice.com
These factors, known as the Body mass index, airflow Obstruction, Dyspnea, and Exercise (BODE) index, can be used to provide information on prognosis for 1-year, 2-year, and 4-year survival.[256]Celli BR, Cote CG, Marin JM, et al. The Body-mass index, airflow Obstruction, Dyspnea, and Exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004 Mar 4;350(10):1005-12.
https://www.nejm.org/doi/full/10.1056/NEJMoa021322
http://www.ncbi.nlm.nih.gov/pubmed/14999112?tool=bestpractice.com
One study revealed that plasma pro-adrenomedullin concentration plus BODE index is a better prognostic tool than BODE index alone.[257]Stolz D, Kostikas K, Blasi F, et al. Adrenomedullin refines mortality prediction by the BODE index in COPD: the "BODE-A" index. Eur Respir J. 2014 Feb;43(2):397-408.
http://www.ncbi.nlm.nih.gov/pubmed/23794469?tool=bestpractice.com
Elevation of adrenomedullin, arginine vasopressin, atrial natriuretic peptide, and C-reactive protein is associated with increased risk of death in patients with stable COPD.[258]Leuzzi G, Galeone C, Taverna F, et al. C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis. Eur Respir Rev. 2017 Jan 31;26(143):160070.
https://err.ersjournals.com/content/26/143/160070
http://www.ncbi.nlm.nih.gov/pubmed/28143876?tool=bestpractice.com
[259]Stolz D, Meyer A, Rakic J, et al. Mortality risk prediction in COPD by a prognostic biomarker panel. Eur Respir J. 2014 Dec;44(6):1557-70.
http://www.ncbi.nlm.nih.gov/pubmed/25034566?tool=bestpractice.com
UK guidelines do not recommend using the BODE index to assess prognosis.[2]National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. Jul 2019 [internet publication].
https://www.nice.org.uk/guidance/ng115
Recently, more interest has been put on comorbidities and prior exacerbations as the predictor of COPD course. CODEX index (comorbidities, obstruction, dyspnea, and previous severe exacerbations) is proved to be superior to BODE index in predicting prognosis for patients with COPD.[260]Almagro P, Soriano JB, Cabrera FJ, et al; Working Group on COPD, Spanish Society of Internal Medicine. Short- and medium-term prognosis in patients hospitalized for COPD exacerbation: the CODEX index. Chest. 2014 May;145(5):972-80.
http://www.ncbi.nlm.nih.gov/pubmed/24077342?tool=bestpractice.com
Frequent COPD exacerbations and requirement for multiple intubation and invasive mechanical ventilation for acute respiratory failure in patients with COPD are markers of poor prognosis.[261]Gunen H, Hacievliyagil SS, Kosar F, et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J. 2005 Aug;26(2):234-41.
https://erj.ersjournals.com/content/26/2/234
http://www.ncbi.nlm.nih.gov/pubmed/16055870?tool=bestpractice.com
Among different therapeutic modalities in COPD, the only two factors that improve survival are smoking cessation and oxygen supplementation.
[
BODE Index for COPD Survival Prediction
Opens in new window
]